The first participant has been dosed in a 40-subject Phase 1 clinical trial evaluating ESSA Pharma’s (NASDAQ:EPIX) EPI-7386 in patients with metastatic castration-resistant prostate cancer who have failed to respond to standard-of-care therapies.
The primary efficacy measure is the proportion of patients achieving at least a 50% decrease in PSA through month 5.
The estimated primary completion date is August 2022.
EPI-7386 is an orally available small molecule inhibitor of the N-terminal domain of the androgen receptor.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.